Circulating mitochondrial DNA signature in cardiometabolic patients
Authors' conclusion
Patients with HF and diabetes have an altered circulating mtDNA signature characterised by higher cell-free mtDNA and lower mtDNA ratio, whereas cellular mtDNA remains unaffected. Cell-free mtDNA and mtDNA ratio are associated with impaired response to exercise, higher systemic inflammation and increased congestion. Circulating mitochondrial profile could be a new biomarker of mitochondrial status in cardiometabolic diseases.
Study context
- Population
- Consecutive patients with T2D and/or heart failure (HF) or at risk of HF; 42/120 (35%) had diabetes
- Participants
- 120 consecutive patients
- Exposure
- Circulating mitochondrial DNA (mtDNA) profile across HF and preserved ejection fraction (HFpEF), HF and reduced ejection fraction (HFrEF) and patients at risk of HF; with vs without diabetes
- HFpEFn = 50
- HFrEFn = 40
- At risk of HFn = 30reference
- Outcome
- Circulating cell, cell-free mtDNA and cell/cell-free mtDNA ratio
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
- Cell/cell-free mtDNA ratio showed opposite trends
- all p < 0.05
Observational data: associations, not effects.
Further findings
Prediction of ≥ 2 ultrasound signs of congestion and effort intolerance (peak oxygen consumption < 16 mL/kg/min)
- Cell-free mtDNA and mtDNA ratio independently predicted both, at ROC analysis and multivariable regression adjusted for age, sex, hs-CRP, NLR, high-sensitivity Troponin T and NT-proBNP
Original publication
Circulating mitochondrial DNA signature in cardiometabolic patients. Cardiovasc Diabetol. Published 5 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →